Filing Details
- Accession Number:
- 0000899243-21-002179
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2021-01-15 16:05:08
- Reporting Period:
- 2021-01-13
- Accepted Time:
- 2021-01-15 16:05:08
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1731831 | Eidos Therapeutics Inc. | EIDX | Pharmaceutical Preparations (2834) | 463733671 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1742587 | Uma Sinha | C/O Eidos Therapeutics, Inc. 101 Montgomery Street, Suite 2000 San Francisco CA 94104 | Chief Scientific Officer | Yes | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Disposition | 2021-01-13 | 696 | $121.11 | 315,829 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2021-01-13 | 572 | $122.27 | 315,257 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2021-01-13 | 1,498 | $123.48 | 313,759 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2021-01-13 | 4,934 | $124.72 | 308,825 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2021-01-13 | 2,000 | $125.35 | 306,825 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2021-01-13 | 300 | $126.39 | 306,525 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct |
Footnotes
- This transaction was effected pursuant to a Rule 10b5-1 Sales Plan adopted by the Reporting Person on August 13, 2020.
- Represents the weighted average sale price of the shares sold ranging from $120.81 to $121.33 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes 2 through 7.
- Represents the weighted average sale price of the shares sold ranging from $121.98 to $122.89 per share.
- Represents the weighted average sale price of the shares sold ranging from $123.01 to $124.00 per share.
- Represents the weighted average sale price of the shares sold ranging from $124.10 to $125.09 per share.
- Represents the weighted average sale price of the shares sold ranging from $125.11 to $125.66 per share.
- Represents the weighted average sale price of the shares sold ranging from $126.30 to $126.57 per share.
Billionaire Hedge Funds
